Literature DB >> 17524839

Value of the tuberculin skin test in screening for tuberculosis in dialysis patients.

M A Habesoğlu1, D Torun, Y Z Demiroglu, M Karatasli, N Sen, H Ermis, Nurhan Ozdemir, F O Eyuboglu.   

Abstract

BACKGROUND: Hemodialysis patients are at high risk for tuberculosis, and a tuberculin skin test (TST) is not usually helpful in detecting tuberculosis infection because of anergic reactions. Prophylactic therapy against tuberculosis in dialysis patients is important to enhance transplantation success. Herein we evaluated the value of TST in screening for tuberculosis and analyzed any compounding factors that might affect the results of the test in hemodialysis patients in an endemic area of Turkey.
METHODS: A total of 187 (96 female, 91 male) patients were screened using a 2-step TST. Test results were compared with clinical, radiologic, and laboratory data.
RESULTS: None of the patients had active tuberculosis during the study and 55% had been vaccinated against tuberculosis. After the first purified protein derivative (PPD) test, 55.1% of the patients showed a positive reaction, ultimately reaching a total of 68.4% following the second test. Cumulative positive TST results were significantly correlated with male gender (P=.001, r=.352), previous tuberculosis history (P=.013, r=.183) positively, whereas with the ferritin level (P=.001, r=-.233) negatively; but there were no significant relationships between TST results and other data.
CONCLUSIONS: Impairment of delayed-type hypersensitivity reaction is frequent in dialysis patients, but we observed high rates of positivity with the two-step TST which could be attributed to tuberculosis being endemic in Turkey. Further comparative studies with more specific diagnostic methods will be helpful to evaluate the importance of TST positivity in identifying tuberculosis-infected HD patients.

Entities:  

Mesh:

Year:  2007        PMID: 17524839     DOI: 10.1016/j.transproceed.2007.02.035

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

1.  A case of disseminated tuberculosis after the initiation of hemodialysis.

Authors:  Jumpei Hasegawa; Sachiko Wakai
Journal:  CEN Case Rep       Date:  2013-04-10

2.  Comparison of the tuberculin skin test and interferon-γ release assay for the diagnosis of latent tuberculosis infection before kidney transplantation.

Authors:  S Y Kim; G S Jung; S K Kim; J Chang; M S Kim; Y S Kim; Y A Kang; D J Joo
Journal:  Infection       Date:  2012-07-17       Impact factor: 3.553

3.  Effect of micronutrient deficiency on QuantiFERON-TB Gold In-Tube test and tuberculin skin test in diagnosis of childhood intrathoracic tuberculosis.

Authors:  A Mukherjee; S Saini; S K Kabra; N Gupta; V Singh; S Singh; S Bhatnagar; D Saini; H M S Grewal; R Lodha
Journal:  Eur J Clin Nutr       Date:  2013-10-30       Impact factor: 4.016

4.  Tuberculin skin test for the diagnosis of latent tuberculosis during renal replacement therapy in an endemic area: A single center study.

Authors:  S K Agarwal; S Gupta; D Bhowmik; S Mahajan
Journal:  Indian J Nephrol       Date:  2010-07

5.  Value of the tuberculin skin testing and of an interferon-gamma release assay in haemodialysis patients after exposure to M. tuberculosis.

Authors:  Luis Anibarro; Matilde Trigo; Diana Feijoó; Mónica Ríos; Luisa Palomares; Alberto Pena; Marta Núñez; Carlos Villaverde; África González-Fernández
Journal:  BMC Infect Dis       Date:  2012-08-20       Impact factor: 3.090

6.  Tuberculosis in haemodialysis patients: A single centre experience.

Authors:  T Manmadha Rao; R Ram; G Swarnalatha; B H Santhosh Pai; V Ramesh; C Shyam Sunder Rao; G Diwaker Naidu; K V Dakshinamurty
Journal:  Indian J Nephrol       Date:  2013-09

7.  Value of gamma interferon enzyme-linked immunospot assay in the diagnosis of peritoneal dialysis-associated tuberculous peritonitis.

Authors:  Qiuxia Fan; Xiaoyan Huang; Jieyun Zhang; Yinan Sun; Zuying Xiong; Zibo Xiong
Journal:  Int Urol Nephrol       Date:  2021-07-14       Impact factor: 2.370

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.